KAT6A/B 抑制剂的帽子：一种针对雌激素受体阳性乳腺癌的新方法。
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
发表日期：2023 Oct 19
作者：
Rinath Jeselsohn, Kornelia Polyak
来源：
Cell Chemical Biology
摘要：
由于 KAT6A 在人类癌症中的致癌作用，人们一直在积极寻找组蛋白乙酰转移酶 (HAT) KAT6 家族的抑制剂。 CTx-648 是一种新型 KAT6A/B 抑制剂，具有优异的药代动力学特性和体内疗效，代表了一种有前景的雌激素受体阳性乳腺癌新治疗策略。版权所有 © 2023 Elsevier Ltd。保留所有权利。
Inhibitors for the KAT6 family of histone acetyltransferases (HATs) have been actively pursued due to the oncogenic roles of KAT6A in human cancer. CTx-648 is a novel KAT6A/B inhibitor with excellent pharmacokinetic properties and in vivo efficacy that represents a promising new treatment strategy for estrogen-receptor-positive breast cancer.Copyright © 2023 Elsevier Ltd. All rights reserved.